Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.21.4
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Condensed Consolidated Statements of Operations (Unaudited)        
Revenues $ 0 $ 0 $ 0 $ 0
Operating Expenses:        
Research and development 639,000 12,000 2,279,000 336,000
Selling, general and administrative (including $14,873,000 of stock compensation to officers and directors in 2021 during the six months ended June 30, 2021) 3,742,000 1,546,000 31,104,000 2,292,000
Loss from Operations 4,381,000 1,558,000 33,383,000 2,628,000
Other (Income) Expense        
Change in fair value of derivative liability 480,000 0 459,000 0
Settlement expense 0 11,206,000 0 11,206,000
Interest expense 0 4,658,000 696,000 5,296,000
Total Other Expense, net 480,000 15,864,000 1,155,000 16,502,000
Net Loss $ (4,861,000) $ (17,422,000) $ (34,538,000) $ (19,130,000)
Net loss per share Basic and diluted $ (0.15) $ (4.12) $ (1.39) $ (4.58)
Weighted average common shares outstanding Basic and diluted 33,516,428 4,229,408 24,925,908 4,175,211